TickerFacts.

Artiva Biotherapeutics, Inc. (ARTV): Capital Expenditures

Annual figures by period end, from SEC filings.

$2.59M
Year ended 2025-12-31
$1.68M
Trailing 12 months to 2026-06-30
$3.26M2023-12-31: $3.26M2024-12-31: $642.0K2025-12-31: $2.59M$2.59M
2023-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$2.59M+303.0%2026-03-10, From 2025-01-01
2024-12-31$642.0K-80.3%2026-03-10, From 2024-01-01
2023-12-31$3.26Mn/a2025-03-24, From 2023-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$2.59M+303.0%
Vaxart, Inc. (VXRT)2025-12-31$145.0K-73.8%
Amgen Inc (AMGN)2025-12-31$1.86B+69.5%
Repligen Corp (RGEN)2025-12-31$23.52M-8.4%
Champions Oncology, Inc. (CSBR)2026-04-30$564.0K+45.0%
Bio-Techne Corp (TECH)2026-06-30$28.85M-7.0%
Biogen Inc. (BIIB)2025-12-31$153.80M+0.1%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$522.0K-7.6%
Gilead Sciences, Inc. (GILD)2025-12-31$563.00M+7.6%

Compare ARTV, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗